<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40051">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733823</url>
  </required_header>
  <id_info>
    <org_study_id>DAHANCA 28A</org_study_id>
    <nct_id>NCT01733823</nct_id>
  </id_info>
  <brief_title>Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole</brief_title>
  <acronym>DAHANCA28A</acronym>
  <official_title>Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Head and Neck Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Head and Neck Cancer Group</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      P16 negative cancers continue to have a dismal prognosis despite advances in the treatment
      of head and neck cancer. Acceleration, dose-escalation, hyperfractionation, chemotherapy and
      nimorazole has been shown to improve local control. The purpose of the study i to
      investigate the level of co-morbidity and performance status (PS) that allows the
      combination of all of the above means of treatment intensification
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compliance</measure>
    <time_frame>End of radiotherapy (approximately 5.5 weeks after start of radiotherapy)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of patients that receive radiotherapy in accordance to prescribed dose and treatment time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>2 months after end of radiotherapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In accordance with the Danish Head and Neck Cancer Group (DAHANCA) toxicity scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 months after end of radiotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of complete and partial responders</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HNSCC,Larynx, Pharynx and Oral Cavity</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PS 0-1 Charlson &gt;=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Squamous Cell Carcinoma head and neck cancer of the pharynx, larynx and oral cavity

          -  P16 negative

          -  T1-4

          -  N1-3

          -  M0

          -  Organ function and performance status allowing radical chemo-radiotherapy

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Overgaard, DrMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Head and Neck Cancer Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Overgaard, DrMSc</last_name>
    <phone>+45 78462620</phone>
    <email>jens@oncology.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kenneth Jensen, PhD</last_name>
    <phone>+45 78460000</phone>
    <email>kennjens@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus</name>
      <address>
        <city>Aarhus</city>
        <state>Aarhus C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Jensen, PhD</last_name>
      <phone>+45 78460000</phone>
      <email>kennjens@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Kenneth Jensen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense</name>
      <address>
        <city>Odense</city>
        <state>Odense C</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Grau Eriksen, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jesper Grau Eriksen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aalborg</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Juhler Andersen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lisbeth Juhler Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elo ANdersen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elo Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>November 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Nimorazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
